Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

ClinicalTrials.gov ID: NCT03651128

Public ClinicalTrials.gov record NCT03651128. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Study identification

NCT ID
NCT03651128
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Celgene
Industry
Enrollment
386 participants

Conditions and interventions

Interventions

  • bb2121 Biological
  • Daratumumab Drug
  • Pomalidomide Drug
  • Dexamethasone Drug
  • Bortezomib Drug
  • Ixazomib Drug
  • Lenalidomide Drug
  • Carfilzomib Drug
  • Elotuzumab Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 15, 2019
Primary completion
Apr 12, 2026
Completion
Apr 12, 2026
Last update posted
Jun 21, 2026

2019 – 2026

United States locations

U.S. sites
36
U.S. states
24
U.S. cities
29
Facility City State ZIP Site status
Local Institution - 109 Birmingham Alabama 10016
Local Institution - 141 Scottsdale Arizona 85259
Local Institution - 145 Los Angeles California 90048
Local Institution - 122 Los Angeles California 90095
Local Institution - 124 Palo Alto California 94304
Local Institution - 142 Aurora Colorado 80045
Local Institution - 108 Jacksonville Florida 32224
Local Institution - 102 Tampa Florida 33612
Local Institution - 131 Atlanta Georgia 30322
Local Institution - 140 Atlanta Georgia 30342
Local Institution - 139 Chicago Illinois 60611
Local Institution - 100 Indianapolis Indiana 46202-528
Local Institution - 112 Westwood Kansas 66205-2003
Local Institution - 104 Baltimore Maryland 21201-1595
Local Institution - 134 Boston Massachusetts 02114
Local Institution - 123 Boston Massachusetts 02215
Local Institution - 120 Ann Arbor Michigan 48109-5936
Local Institution - 125 Rochester Minnesota 55905-0001
Local Institution - 114 St Louis Missouri 63110
University Of Nebraska Omaha Nebraska 68198-7680
Local Institution - 138 Hackensack New Jersey 07601
Local Institution - 119 New York New York 10029
Local Institution - 115 New York New York 10065
Local Institution - 135 New York New York 10065
Local Institution - 113 Durham North Carolina 27705
Local Institution - 111 Philadelphia Pennsylvania 19107
Local Institution - 110 Philadelphia Pennsylvania 19111
Local Institution - 101 Pittsburgh Pennsylvania 15232
Local Institution - 106 Nashville Tennessee 37203
Local Institution - 118 Dallas Texas 75246
Local Institution - 103 Dallas Texas 75390
Local Institution - 132 Houston Texas 77030
Local Institution - 136 Salt Lake City Utah 84112
Local Institution - 105 Seattle Washington 98104
Local Institution - 107 Madison Wisconsin 53792
Froedtert Hospital BMT Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03651128, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2026 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03651128 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →